524632 Stock Overview
Develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 6/6 |
Financial Health | 5/6 |
Dividends | 3/6 |
Shukra Pharmaceuticals Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹67.87 |
52 Week High | ₹129.90 |
52 Week Low | ₹21.29 |
Beta | 0.25 |
11 Month Change | -2.22% |
3 Month Change | -11.43% |
1 Year Change | 177.50% |
33 Year Change | 464.99% |
5 Year Change | 439.19% |
Change since IPO | 74.03% |
Recent News & Updates
Recent updates
Shareholder Returns
524632 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -3.9% | 3.0% | 1.6% |
1Y | 177.5% | 54.1% | 36.9% |
Return vs Industry: 524632 exceeded the Indian Pharmaceuticals industry which returned 54.1% over the past year.
Return vs Market: 524632 exceeded the Indian Market which returned 36.9% over the past year.
Price Volatility
524632 volatility | |
---|---|
524632 Average Weekly Movement | 7.2% |
Pharmaceuticals Industry Average Movement | 6.3% |
Market Average Movement | 6.2% |
10% most volatile stocks in IN Market | 9.3% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 524632 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 524632's weekly volatility (7%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 182 | Dakshesh Shah | www.shukrapharmaceuticals.com |
Shukra Pharmaceuticals Limited develops, manufactures, markets, and exports various drugs and dosage forms in India and internationally. Its product portfolio includes macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, muscle relaxants, anti tuberculosis, vitamin products, anti allergics, corticosteroids, hyper and hypoglycemic, and other products, as well as antibiotics, such as penicillin and cephalosporin. The company was formerly known as Relish Pharmaceuticals Limited and changed its name to Shukra Pharmaceuticals Limited in August 2016.
Shukra Pharmaceuticals Limited Fundamentals Summary
524632 fundamental statistics | |
---|---|
Market cap | ₹2.97b |
Earnings (TTM) | ₹186.02m |
Revenue (TTM) | ₹604.90m |
16.0x
P/E Ratio4.9x
P/S RatioIs 524632 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
524632 income statement (TTM) | |
---|---|
Revenue | ₹604.90m |
Cost of Revenue | ₹265.93m |
Gross Profit | ₹338.97m |
Other Expenses | ₹152.95m |
Earnings | ₹186.02m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 4.25 |
Gross Margin | 56.04% |
Net Profit Margin | 30.75% |
Debt/Equity Ratio | 5.5% |
How did 524632 perform over the long term?
See historical performance and comparison